Esperion Therapeutics, Inc.

NasdaqGM:ESPR Rapport sur les actions

Capitalisation boursière : US$805.8m

Esperion Therapeutics Gestion

Gestion contrôle des critères 3/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Sheldon Koenig

Directeur général

US$3.5m

Rémunération totale

Pourcentage du salaire du PDG21.80%
Durée du mandat du directeur général5yrs
Propriété du PDG0.2%
Durée moyenne d'occupation des postes de direction3.8yrs
Durée moyenne du mandat des membres du conseil d'administration3.8yrs

Mises à jour récentes de la gestion

Recent updates

Mise à jour du récit • May 19

ESPR: Vision 2040 Plans And Acquisition Are Weighed Against Downgrade Risks

Esperion Therapeutics' updated analyst price target has moved from about $15.92 to $3.28 as analysts factor in a series of recent downgrades alongside mixed sentiment around execution on longer term plans and pipeline expansion. Analyst Commentary Recent research has been dominated by downgrades, but there are still a few points that bullish analysts highlight when they look at Esperion Therapeutics and its current valuation.
Mise à jour du récit • May 04

ESPR: Vision 2040 And Corstasis Deal Will Balance Downgrade Concerns

Narrative Update on Esperion Therapeutics The updated analyst price target for Esperion Therapeutics has moved closer to recent Street views, rising from a fair value estimate of $1.78 to $3.16. Analysts are weighing recent downgrades against research that cites consistent Q4 results, progress on the Vision 2040 plan, and pipeline expansion, including the Corstasis Therapeutics acquisition and ESP-2001 advancement.
Mise à jour du récit • Apr 20

ESPR: Vision 2040 Progress Will Likely Mask Corstasis Execution Risk

Analysts recently lifted their price target on Esperion Therapeutics to $5 from $4, citing Q4 results that aligned with earlier guidance and continued progress on the Vision 2040 plan, including the Corstasis Therapeutics acquisition and advancement of ESP-2001. Analyst Commentary Recent commentary around Esperion focuses on how the updated US$5 price target lines up with the company’s execution on its Vision 2040 plan.
Mise à jour du récit • Apr 06

ESPR: Vision 2040 And Corstasis Deal Will Likely Expose Execution Risks

Analysts raised their price target on Esperion Therapeutics to $5 from $4, citing the company's Q4 results, continued execution of its Vision 2040 plans, the acquisition of Corstasis Therapeutics, and progress with ESP-2001 as key reasons for the update. Analyst Commentary The latest research update highlights that the higher US$5 price target reflects Q4 results that were in line with January guidance, along with continued execution of the Vision 2040 plans.
Mise à jour du récit • Mar 23

ESPR: Vision 2040 Execution And ESP-2001 Progress Will Drive Future Upside

Narrative Update Overview Analysts have lifted their price target on Esperion Therapeutics to $5, up from $4, citing continued execution on Vision 2040, the Corstasis Therapeutics acquisition, and progress with ESP-2001 as key drivers behind the updated valuation inputs. These inputs include a higher fair value estimate and adjusted discount rate and P/E assumptions.
Mise à jour du récit • Mar 09

ESPR: Patent Litigation Outcomes Will Likely Expose Weak Profitability Execution Risks

Analysts have revised their price target for Esperion Therapeutics to align with updated assumptions that keep fair value steady at about $1.78 per share. This reflects higher modeled revenue growth, balanced by lower projected profit margins and a slightly reduced future P/E multiple.
Mise à jour du récit • Feb 22

ESPR: Overweight Rating Will Likely Conceal Risk Around Patent And Profitability Execution

Analysts have adjusted their price target on Esperion Therapeutics to $9, reflecting updated assumptions for revenue growth, profit margin, and forward P/E. This change is supported by recent Street research highlighting the new coverage and target level.
Mise à jour du récit • Feb 08

ESPR: Overweight Rating Will Likely Mask Execution Risk Around Acquisition Strategy

Analysts have raised their price target for Esperion Therapeutics to about US$1.78 from roughly US$1.72, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E. These changes reflect the recent US$9 initiation from Piper Sandler as part of a broader reassessment of the stock's earnings power and risk profile.
Mise à jour du récit • Jan 24

ESPR: Overweight Rating And Accretive Deal Hunt Will Support Bullish Sentiment

Analysts have nudged their price target for Esperion Therapeutics slightly higher to around US$6.50, citing updated assumptions for revenue growth, profit margin and future P/E that are generally consistent with recent Street research, including the new US$9 target from Piper Sandler. Analyst Commentary Analysts are using the new US$9 reference point to frame both the upside case and the key execution questions around Esperion Therapeutics, with the latest work focusing on how current assumptions for revenue, profit margin and future P/E might play out over time.
Mise à jour du récit • Jan 07

ESPR: Overweight Rating Will Likely Obscure Persistent Execution And Profitability Risks

Narrative Update on Esperion Therapeutics Analysts have lifted their price target on Esperion Therapeutics to US$9, citing updated assumptions for revenue growth, profitability, and future P/E that reflect a more constructive view of the company’s earnings potential. Analyst Commentary Recent coverage highlights a more constructive stance on Esperion Therapeutics, with a US$9 price target used as a reference point for what the business might be worth if current assumptions on revenue and earnings play out as expected.
Mise à jour du récit • Dec 23

ESPR: Rising Street Optimism Will Likely Mask Lingering Execution Risks

Analysts have raised their price target on Esperion Therapeutics to $9.00 from $7.00, reflecting increased confidence in the stock's valuation despite moderating long term growth and margin assumptions. Analyst Commentary Recent Street research has reflected a cautiously optimistic stance toward Esperion Therapeutics, with new coverage and revised price targets coalescing around the $9 level.
Mise à jour du récit • Dec 09

ESPR: Rising Overweight Ratings Will Support Bullish Sentiment Toward Shares

Analysts have nudged their price target for Esperion Therapeutics higher to approximately $6.50 per share from about $6.15, citing supportive Street research, including recent Overweight initiations and target increases. These changes reflect confidence in the company’s longer term earnings multiple despite slightly tempered growth and margin assumptions.
Mise à jour du récit • Nov 25

ESPR: Overweight Ratings And Positive Developments Will Strengthen Bullish Outlook For Shares

Analysts have raised their price target for Esperion Therapeutics from $7 to $9 per share. This reflects improved expectations for the company's revenue growth and fair value based on recent positive coverage and outlook updates.
Mise à jour du récit • Nov 09

ESPR: Price Target Increase Will Drive Renewed Confidence In Future Performance

Analysts have raised their price target for Esperion Therapeutics from $7 to $9, citing improved growth and profitability expectations. Analyst Commentary Bullish Takeaways Bullish analysts have increased their price targets, reflecting growing confidence in the company's outlook and execution capabilities.
Seeking Alpha • Sep 09

Esperion: A Mixture Of Opportunity And Risk: Why I Would Hold For Now

Summary Esperion's stock surged over 30% this month after Q2 results beat expectations, driven by strong U.S. sales and global partnerships. The company benefits from high-margin collaboration revenues and expanding international milestones but faces heavy debt and declining cash reserves. Patent settlements protect U.S. exclusivity through 2040, yet ongoing litigation and financial strain add significant risk to the investment thesis. Given the mix of opportunity and risk, I assign a Hold rating until Esperion demonstrates consistent profitability and improved financial stability. Read the full article on Seeking Alpha
Mise à jour du récit • Aug 06

Rising Digital Adoption And Global Partnerships Will Shape Future Markets

Esperion Therapeutics' consensus price target has increased as analysts now assign a higher future P/E despite a decline in net profit margin, resulting in the APT rising from $5.79 to $6.50. What's in the News Esperion Therapeutics was dropped from the S&P Pharmaceuticals Select Industry Index.
User avatar
Nouveau récit • May 04

US FDA Approvals And Global Expansion Will Shape Future Markets

International expansion and strategic partnerships are anticipated to significantly boost global sales and royalty revenues over time.
Seeking Alpha • Feb 22

Esperion Therapeutics: Little Upside Potential In Their Earlier Generation Drug

Summary Esperion Therapeutics has two approved LDL-C lowering therapies, Nexletol and Nexlizet, but lacks a strong pipeline for future growth. Recent label expansions for Nexletol and Nexlizet have broadened their indications, but competition from Merck's PCSK9 inhibitor could impact ESPR's market position. Financially, Esperion has limited cash runway and faces challenges from more effective and safer LDL-C lowering treatments like PCSK9 inhibitors. Despite trading near 52-week lows, I see little upside in investing in Esperion due to its moderate benefits and lack of a robust pipeline. Read the full article on Seeking Alpha
Seeking Alpha • Dec 08

Will The Long Awaited Breakout For Esperion Therapeutics Hold?

Summary Esperion Therapeutics' stock broke out above a year-long trading range, signaling a potential sustainable breakout if support at $3.40 holds. Despite past skepticism and price fades, recent technical achievements and strategic moves, including global drug submissions, bolster the stock's outlook. The Piper Sandler Conference reinforced Esperion's growth strategy, with CEO Sheldon Koenigand CFO Ben Halladay providing encouraging news on guidance and business performance. Insider ownership remains low, which could impact confidence, but the company's strategic positioning and milestones present a compelling investment case. Read the full article on Seeking Alpha
Seeking Alpha • Nov 13

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

Summary I maintain my buy rating on Esperion Therapeutics due to its strong Q3 2024 financial performance, showcasing consistent revenue growth and market adoption. The Company's aggressive commercialization efforts, including market coverage expansion and sales force growth, have significantly boosted retail prescriptions and broadened future revenue streams. International expansion through partnerships with Daiichi Sankyo Europe and Otsuka Pharmaceutical has driven prescription and revenue growth, strengthening ESPR's global presence. Technical analysis indicates bullish momentum with no signs of reversal, supported by positive financials and key growth drivers, making ESPR a buy. Read the full article on Seeking Alpha
Seeking Alpha • Aug 16

Esperion Therapeutics: Strategically Positioned To Grow

Summary Esperion is a pharmaceutical firm whose focus is to treat patients with high low-density lipoprotein cholesterol (LDL-C). I rate it a buy due to strategic initiatives and market potential driving significant growth. Strong revenue growth and margin expansions reflect improving financial performance and market breakthrough. ESPR's unique non-statin medicines address unmet demand, offering a competitive advantage in the large and growing LDL-C-lowering pharmaceutical market. Read the full article on Seeking Alpha
Seeking Alpha • May 20

Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock

Summary Esperion Therapeutics secured FDA approval for expanded labels of its flagship drugs and obtained a patent extension. Despite these successes, the stock trades with the weight of an abiding skepticism. The company's Q1 showed accelerating revenue growth, but guidance offered little new information. A lipid lurker marketing campaign shows early top of the funnel success, but there is little data yet to demonstrate bottom funnel performance. Still, with the stock trading at a valuation discount, I continue to buy ESPR in expectation of significant upside once the company shows evidence of exponential growth and healthy profitability. Read the full article on Seeking Alpha
Seeking Alpha • Feb 28

A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics

Summary Esperion Therapeutics reported strong Q4 and full-year revenue growth, with total revenue increasing 72% YoY to $32.3M in Q4 and 54% YoY to $116M for the full year. The company expects a true inflection point after receiving approval for expanded labels for its cardiovascular drugs. Esperion is preparing for a significant sales ramp starting in April, with an expanded sales force and an anticipated larger patient population. Read the full article on Seeking Alpha
Seeking Alpha • Jan 22

Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations

Summary Esperion Therapeutics' stock gapped down after news of a stock offering but fortunately never reached the $1.50 offering price. The presentation at the JP Morgan Healthcare Conference provided little new information and failed to boost the stock. The Q&A session provided some insights, including information about utilization management headwinds and the company's digital consumer campaign. Altogether, the company appears to be stuck in a "prove it" box and needs to demonstrate a compelling path to profitability to maintain interest in investing in the promise of its drugs. Read the full article on Seeking Alpha
Seeking Alpha • Jan 14

Esperion Is Sitting On A Potential Blockbuster Drug

Summary Esperion Therapeutics has a potential blockbuster drug that is gaining traction among the medical community. The company's main drugs, NEXLIZET and NEXLETOL, have been approved by the FDA and offer alternatives to statins for lowering LDL cholesterol. Recent developments, including an expanded labeling and influential endorsements from doctors like Peter Attia, suggest potential growth for the company. Read the full article on Seeking Alpha
Article d’analyse • Jun 19

Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Esperion Therapeutics, Inc.'s ( NASDAQ:ESPR ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a buy...
Article d’analyse • Mar 09

Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Shareholders in Esperion Therapeutics, Inc. ( NASDAQ:ESPR ) may be thrilled to learn that the analysts have just...
Article d’analyse • Feb 23

Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Market forces rained on the parade of Esperion Therapeutics, Inc. ( NASDAQ:ESPR ) shareholders today, when the analysts...

Analyse de la rémunération des PDG

Comment la rémunération de Sheldon Koenig a-t-elle évolué par rapport aux bénéfices de Esperion Therapeutics?
DateRémunération totaleSalaireBénéfices de l'entreprise
Mar 31 2026n/an/a

-US$7m

Dec 31 2025US$4mUS$771k

-US$23m

Sep 30 2025n/an/a

-US$106m

Jun 30 2025n/an/a

-US$104m

Mar 31 2025n/an/a

-US$153m

Dec 31 2024US$3mUS$746k

-US$52m

Sep 30 2024n/an/a

-US$87m

Jun 30 2024n/an/a

-US$98m

Mar 31 2024n/an/a

-US$87m

Dec 31 2023US$3mUS$721k

-US$209m

Sep 30 2023n/an/a

-US$208m

Jun 30 2023n/an/a

-US$222m

Mar 31 2023n/an/a

-US$239m

Dec 31 2022US$4mUS$683k

-US$234m

Sep 30 2022n/an/a

-US$243m

Jun 30 2022n/an/a

-US$258m

Mar 31 2022n/an/a

-US$235m

Dec 31 2021US$8mUS$566k

-US$269m

Sep 30 2021n/an/a

-US$308m

Jun 30 2021n/an/a

-US$325m

Mar 31 2021n/an/a

-US$156m

Dec 31 2020US$508kUS$23k

-US$144m

Rémunération vs marché: La rémunération totale de Sheldon ($USD 3.54M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 3.73M ).

Rémunération et revenus: La rémunération de Sheldon a augmenté alors que l'entreprise n'est pas rentable.

PDG

Sheldon Koenig (59 yo)

5yrs
Titularisation
US$3,535,512
Compensation

Mr. Sheldon L. Koenig, M.B.A. is Business Advisor Sarcomatrix Therapeutics, Corp. Mr. Koenig has been President, Chief Executive Officer and Director at Esperion Therapeutics, Inc. since May 17, 2021 and h...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Sheldon Koenig
President5yrsUS$3.54m0.22%
$ 1.8m
Benjamin Halladay
Chief Financial Officer3.5yrsUS$1.35m0.075%
$ 601.3k
John Harlow
Chief Commercial Officerless than a yearUS$3.29m0.16%
$ 1.3m
Glenn Brame
Chief Technical Operations Officer3.3yrspas de donnéespas de données
Benjamin Looker
Chief Legal & Corporate Affairs Officer4.3yrsUS$1.13m0.060%
$ 486.4k
Tiffany Aldrich
Associate Director of Corporate Communicationsno datapas de donnéespas de données
Betty Swartz
Chief Business Officer4.2yrspas de donnéespas de données
LeAnne Bloedon
VP & Head of Developmentno datapas de donnéespas de données
Stephen Pinkosky
Vice President of Drug Discovery of Early Pre-Clinical Developmentno datapas de donnéespas de données
3.8yrs
Durée moyenne de l'emploi
49yo
Âge moyen

Gestion expérimentée: L'équipe de direction de ESPR est considérée comme expérimentée (ancienneté moyenne 3.8 ans).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Sheldon Koenig
President5yrsUS$3.54m0.22%
$ 1.8m
Robert Hoffman
Independent Director1.1yrsUS$86.38k0.0021%
$ 16.5k
Jay Shepard
Independent Director8yrsUS$127.71k0.033%
$ 264.8k
Stephen Rocamboli
Independent Director4.1yrsUS$124.70k0.027%
$ 216.8k
J. Carroll
Independent Chairperson3.9yrsUS$152.20k0.038%
$ 305.6k
Peter Libby
Member of Scientific Advisory Board3.8yrspas de donnéespas de données
Seth H. Fischer
Independent Director4.6yrsUS$132.71k0.024%
$ 191.4k
Tracy Woody
Independent Director7yrsUS$129.21k0.013%
$ 105.1k
R. Mason
Member of Scientific Advisory Board3.8yrspas de donnéespas de données
David Cohen
Member of Scientific Advisory Board3.8yrspas de donnéespas de données
Karin Bornfeldt
Member of Scientific Advisory Board3.8yrspas de donnéespas de données
Pradeep Natarajan
Member of Scientific Advisory Board3.8yrspas de donnéespas de données
3.8yrs
Durée moyenne de l'emploi
63yo
Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de ESPR sont considérés comme expérimentés (ancienneté moyenne 3.8 ans).

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/21 17:29
Cours de l'action en fin de journée2026/05/21 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Esperion Therapeutics, Inc. est couverte par 16 analystes. 6 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Jason ZemanskyBofA Global Research
Kristen KluskaCantor Fitzgerald & Co.
Jason ButlerCitizens JMP Securities, LLC